University of Manchester spin-out secures £1.75 million investment


Ai2, a spin-out of the University of Manchester, has secured £950,000 from MTI and £800,000 from the North West Fund for Biomedical, managed by Spark Impact. The company has developed proprietary human protein-like substances that safely and cost-effectively inhibit bacteria, fungi and viruses. The products have the potential to be used to prevent infection on a wide range of commonly used medical devices including urinary catheters, stents, orthopaedic implants and wound dressings.
Ai2ís humanised cationic peptides are available for exclusive license., source:

Related News

Fund dedicated to spin-outs


MTI, the venture capital fund manager that runs the University of Manchesterís UMIP Premier Fund, is raising money for a new fund dedicated to university spin-outs.
... read more >

New antimicrobial coating on the way


Researchers at the University of Manchester are working on the development of a new antimicrobial catheter coating that will reduce the need for catheter replacement.... read more >

University of Manchester wants your feedback


The University of Manchester has a dentistry innovation: a device for the real-time imaging of root canal treatments.... read more >

Copyright © 2014 Med-Tech Innovation
Submit Editorial | Media Kit | Privacy Policy | Terms of Service | Site map